- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02985281
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Daul Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection. A Prospective, Randomized, Multicenter Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Male or female child ≥ 10 years and ≤ 18 years of age chronically infected with hepatitis C virus, willing and able to complete all study visits and procedures. Acceptance from the parents will be recruited for giving a verbal and written informed consent. Patient with childs Pugh class B or C, compensated cirrhosis may be enrolled. Patient with cirrhosis with their alpha fetoprotein is more than 100 ng/ml and patient with coinfection of Hepatitis B virus or HIV will be excluded. Participation in the study procedures is anticipated to last up to 40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.
A detailed treatment log of the returned investigational product will be established with the investigator (or the pharmacist) and countersigned by the investigator and the monitoring team.
Compliance is assessed by counting the number of returned tablets at each visit.
A discontinuation is defined as a period with at least seven consecutive days without study drug intake.
Safety and efficacy will be compared between cirrhotic versus non-cirrhotic subjects in multivariate model to test the impact of this pretreatment characteristic on safety, tolerability and efficacy endpoints.
Safety analysis:clinical adverse events will be displayed by body system (soc) for each study subject and by treatment group, using MedDRA coding. Summary of statistics of safety and efficacy endpoints will be displayed by stratification parameters.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Menofia
-
Segin el Kom, Menofia, Egypt, 32714
- National Liver Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female child ≥ 10 years and ≤ 18 years of age chronically infected with hepatitis C virus.
willing and able to complete all study visits and procedures. Acceptance from the parents will be recruited for giving a verbal and written informed consent.
Patient with child,s Pugh class B or C, compensated cirrhosis may be enrolled.
Exclusion Criteria:
- Patient with cirrhosis with their alpha fetoprotein is more than 100 ng/ml.
- Patient with coinfection of hepatitis B virus or Human Immunodeficiency Virus will be excluded.
- Creatinine clearance < 50 ml/minute.
- Albumin<3 gm/dl.
- aspartate aminotransferase or alanine aminotransferase > 10 upper limit of normal.
- Pregnant and lactating females.
- Associated morbidity such as uncontrolled diabetes mellitus, schistosomiasis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1
20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily). Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight. |
direct acting antiviral drug for HCV infection
Other Names:
antiviral drug for HCV infection
|
Active Comparator: Arm 2
20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration. Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily). Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight. |
direct acting antiviral drug for HCV infection
Other Names:
antiviral drug for HCV infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of SVR12 in both treatment groups after 12 following completion of treatment (SVR12)
Time Frame: 40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.
|
incidence of SVR12 in both treatment groups after 12 weeks following completion of treatment (SVR12)
|
40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assessment of the nature, severity and frequency of the adverse effects and absolute values and changes over time from pre-dose values for hematology clinical chemistry, urine analysis, vital signs and ECG parameters.
Time Frame: 40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.
|
Safety and tolerability are assessed by: the nature, severity and frequency of the adverse effects and absolute values and changes over time from pre-dose values for hematology clinical chemistry, urine analysis, vital signs and ECG parameters. Clinical adverse events will be displayed by body system (SOC) for each study subject and by treatment group, using MedDRA coding. Absolute laboratory values, changes and its graded abnormalities will be displayed) for each study subject and by treatment group. The proportions of subjects experiencing Clinical adverse events and laboratory abnormalities of a given type will be computed and presented along with descriptive statistics. Vital signs data will be similarly assessed, and any post baseline changes in physical examination findings will be summarized in tubular form, by subject and by treatment cohort. Summary statistics of efficacy and safety end points will be displayed by stratification parameters |
40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Behairy Behairy, professor, National Liver Institute, Egypt
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00114/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacological Action
-
Universidad Nacional de SaltaFundacion Mundo SanoNot yet recruitingPharmacological Action
-
Federal State Budgetary Scientific Institution,...The League of Clinical Research, Russia; Institute of Biomedical Chemistry,...Completed
-
Masaryk Hospital Usti nad LabemUnknownPharmacological ActionCzechia
-
Ervin TasoUniversity of BelgradeCompletedPharmacological ActionSerbia
-
Tianjin Medical University General HospitalRecruiting
-
Qin ZhangRecruitingPharmacological ActionChina
-
Food and Nutrition Research Institute, PhilippinesAteneo de Manila University; De La Salle Medical and Health Sciences InstituteActive, not recruiting
-
Fudan UniversityShanghai First Maternity and Infant Hospital; Women and children's hospital...UnknownPharmacological ActionChina
-
Kolding SygehusUnknown
-
University of MalayaMinistry of Health, MalaysiaUnknownPharmacokinetics | Molecular Mechanisms of Pharmacological ActionMalaysia
Clinical Trials on Sofosbuvir Oral Product
-
MTI UniversityUnknownEgyptian Patients, HCV Treatment, Kidney FunctionEgypt
-
Ain Shams UniversityCairo UniversityCompletedHepatitis C, Chronic | Hematologic MalignancyEgypt
-
Zagazig UniversityCairo UniversityUnknown
-
Ain Shams UniversityCairo UniversityRecruiting
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
The Third Affiliated Hospital of Guangzhou Medical...RecruitingChronic Hepatitis C | Medication ReactionChina
-
Ohio State UniversityCompletedHepatitis C | HCV | Kidney TransplantUnited States
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
University Hospital, BordeauxCompleted